Abstract | OBJECTIVE: DESIGN: METHODS: The treatment was evaluated using serial analysis of serum parathyroid hormone (PTH) and calcium, clinical evaluation and chest radiographs. RESULTS: Intravenous pamidronate alone had limited effect on hypercalcaemia. Following irradiation of the pulmonary lesions (34 Gy in ten fractions), serum levels of calcium and PTH decreased and pamidronate could be discontinued. The patient's general condition improved parallel to a radiological response. At clinical relapse 18 months following radiotherapy, the pulmonary metastases were resected and serum PTH was normalised. CONCLUSIONS: The results indicate that parathyroid carcinoma can be radiosensitive. Thus radiotherapy may be an alternative to palliate symptoms of hypercalcaemia in patients not suited for surgery.
|
Authors | T Rasmuson, A Kristoffersson, L Boquist |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 143
Issue 6
Pg. 749-54
(Dec 2000)
ISSN: 0804-4643 [Print] England |
PMID | 11124857
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Diphosphonates
- Parathyroid Hormone
- Pamidronate
- Calcium
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Calcium
(blood)
- Combined Modality Therapy
- Diphosphonates
(therapeutic use)
- Female
- Follow-Up Studies
- Humans
- Hypercalcemia
(etiology)
- Lung Neoplasms
(drug therapy, physiopathology, radiotherapy, secondary, surgery)
- Middle Aged
- Pamidronate
- Parathyroid Hormone
(blood)
- Parathyroid Neoplasms
(drug therapy, physiopathology, radiotherapy, surgery)
- Radiography, Thoracic
- Radiotherapy Dosage
- Radiotherapy, Adjuvant
|